Leadership

Led by highly experienced people who already worked together in private and public companies bringing drugs through successful clinical development

Separatore sotto titolo

EXECUTIVE TEAM

STRATEGIC ADVISORS

BOARD OF DIRECTORS

EXECUTIVE TEAM

Silvia Panigone, PhD, EMBA
Chief Executive Officer

25 years in biotech, mid-size private & public, C-level roles & Board positions in Drug development, Investment Banking and VC. Track record of fund raising (over $100M raised), partnership deals and M&A, creating an exit for multiple biotechs. Former COO at NLS (NASDAQ:NLSP). Bracco, Quintiles, I-bankers securities, BSI Healthcapital, ADYA

Alberto Morisetti, PhD
Pharmatox and Pre-clinical Development
Over 30 years of experience in regulatory preclinical pharma-tox and CMC bringing drugs thorugh IND-enabling studies to clinical trials. Extensive eperience with FDA, EMA and other regulatory bodies.
Dr. Carlos Camozzi, MD, PhD
Clinical Development

30 years experience as CMO & Medical Director in private & public biotech & Pharma companies. Succesful track record in clinical study design, implementation and discussion with regulatory bodies in the US & EU, with a strong focus on rare indications.

Joe Garlich, PhD
Scientific Strategy – Research & Development

Co-inventor of SF2523, the API of INHAL-101 small molecule while affiliated with SignalRx. Over 35 years experience in drug discovery & development. Inventor of 29 US patents, 4 NMEs through human PoC. CEO & CSO in a small biotech, raising over $25 million in grants and equity. Former C-level in SignalRx, now partially-retired.

Asha Kattige, PhD (Scendea, Principal Consultant)
Manufacturing – Regulatory CMC

Over 23 years experience in leading CMC projects in the pharma industry across a broad range of therapeutic areas including COPD & IPF, with a focus on inhaled products in solid, liquid and semi-solid forms. Proven track record of defining robust strategies and dossiers ensuring successful registration within the EU, US & RoW.

Qun Shao, PhD Eng.
Drug Product Development

Co-founder and COO at Crystec. Several years experience in tech transfer and manufacturing process scale up in Industry & Academia across China and UK. Director of Healthtech Open Innovation in Bradford and founder of RCUK China Science Bridges programme.

Guillermo Morales, PhD, EMBA
Drug Substance Process Development

Co-inventor of SF2523, the API of INHAL-101, a small molecule discovered while affiliated with SignalRx. Over 25 years experience in big pharma, mid size and start-up. Biotech cofounder; CEO & COO in revenue stage companies. He serves as SBIR/STTR grant reviewer for the NIH, and was Editor-in-Chief of Molecular Diversity. C-level at SignalRx.

Silvia Panigone, PhD, EMBA
Chief Executive Officer

25 years in biotech, mid-size private & public, C-level roles & Board positions in Drug development, Investment Banking and VC. Track record of fund raising (over $100M raised), partnership deals and M&A, creating an exit for multiple biotechs. Former COO at NLS (NASDAQ:NLSP). Bracco, Quintiles, I-bankers securities, BSI Healthcapital, ADYA

Alberto Morisetti, PhD
Pharmatox and Pre-clinical Development
Over 30 years of experience in regulatory preclinical pharma-tox and CMC bringing drugs thorugh IND-enabling studies to clinical trials. Extensive eperience with FDA, EMA and other regulatory bodies.
Dr. Carlos Camozzi, MD, PhD
Clinical Development

30 years experience as CMO & Medical Director in private & public biotech & Pharma companies. Succesful track record in clinical study design, implementation and discussion with regulatory bodies in the US & EU, with a strong focus on rare indications.

Joe Garlich, PhD
Scientific Strategy – Research & Development

Co-inventor of SF2523, the API of INHAL-101 small molecule while affiliated with SignalRx. Over 35 years experience in drug discovery & development. Inventor of 29 US patents, 4 NMEs through human PoC. CEO & CSO in a small biotech, raising over $25 million in grants and equity. Former C-level in SignalRx, now partially-retired.

Asha Kattige, PhD (Scendea, Principal Consultant)
Manufacturing – Regulatory CMC

Over 23 years experience in leading CMC projects in the pharma industry across a broad range of therapeutic areas including COPD & IPF, with a focus on inhaled products in solid, liquid and semi-solid forms. Proven track record of defining robust strategies and dossiers ensuring successful registration within the EU, US & RoW.

Qun Shao, PhD Eng.
Drug Product Development

Co-founder and COO at Crystec. Several years experience in tech transfer and manufacturing process scale up in Industry & Academia across China and UK. Director of Healthtech Open Innovation in Bradford and founder of RCUK China Science Bridges programme.

Guillermo Morales, PhD, EMBA
Drug Substance Process Development

Co-inventor of SF2523, the API of INHAL-101, a small molecule discovered while affiliated with SignalRx. Over 25 years experience in big pharma, mid size and start-up. Biotech cofounder; CEO & COO in revenue stage companies. He serves as SBIR/STTR grant reviewer for the NIH, and was Editor-in-Chief of Molecular Diversity. C-level at SignalRx.

Strategic Advisors

David Schwicker
IPF Product Development Strategy

Founder ORPHA Strategy, expert for accelerating clinical development, marketing authorization, patient, and market access in orphan indications. Recently involved in clinical development planning in IPF, for an oral autotaxin inhibitor, an inhaled Galectin-3 inhibitor and a late-clinical inhaled prostacyclin analog for IPF.

Prof. Peter York, PhD
Technology & Intellectual Property Strategy

Co-founder of Crystec and Co-inventor of mSAS. Founder of Bradford Particle Design Ltd, based on supercritical fluids, acquired by Inhale Therapeutics in 2001 for $200M. Has sat on MHRA and EMEA drug review panels. Emeritus Professor of Physical Pharmaceutics, former member of British Pharmacopoeia Commission.

Emily S. Turilli Ghisolfi, MSc, MBA
Business Intelligence

5 years experience as Adya analyst; competitive intelligence and biotech products analysis; former preclinical project manager in NLS.

Scendea

Scendea is a leading product development and regulatory consulting practice operating globally, with an extensive expertise in inhaled drugs development.

David Schwicker
IPF Product Development Strategy

Founder ORPHA Strategy, expert for accelerating clinical development, marketing authorization, patient, and market access in orphan indications. Recently involved in clinical development planning in IPF, for an oral autotaxin inhibitor, an inhaled Galectin-3 inhibitor and a late-clinical inhaled prostacyclin analog for IPF.

Prof. Peter York, PhD
Technology & Intellectual Property Strategy

Co-founder of Crystec and Co-inventor of mSAS. Founder of Bradford Particle Design Ltd, based on supercritical fluids, acquired by Inhale Therapeutics in 2001 for $200M. Has sat on MHRA and EMEA drug review panels. Emeritus Professor of Physical Pharmaceutics, former member of British Pharmacopoeia Commission.

Emily S. Turilli Ghisolfi, MSc, MBA
Business Intelligence

5 years experience as Adya analyst; competitive intelligence and biotech products analysis; former preclinical project manager in NLS.

Scendea

Scendea is a leading product development and regulatory consulting practice operating globally, with an extensive expertise in inhaled drugs development.

BOARD OF DIRECTORS

Paul Thorning, CEng, MBA
Board Member

Crystec CEO. Former Licensing Director for AstraZeneca (Crestor acquisition team). Serial enterpreneur. Skilled in strategic marketing, product development & product engineering. Professor of Innovation. UK national lead for Health and Innovation with China.

Matt Williams, JD
Board Chairman

SignalRX CEO. Experienced Executive and Managing Shareholder with 40 years experience in the practice of law. Skilled in negotiation, arbitration, mediation, complex transactions, legal writing, complex civil litigation, and appeals. Experienced entrepreneur.

Silvia Panigone, PhD, EMBA
Board Member, CEO

25 years in biotech, mid-size private & public, C-level roles & Board positions in Drug development, Investment Banking and VC. Track record of fund raising (over $100M raised), partnership deals and M&A, creating an exit for multiple biotechs. Former COO at NLS (NASDAQ:NLSP). Bracco, Quintiles, I-bankers securities, BSI Healthcapital, ADYA

Paul Thorning, CEng, MBA
Board Member

Crystec CEO. Former Licensing Director for AstraZeneca (Crestor acquisition team). Serial enterpreneur. Skilled in strategic marketing, product development & product engineering. Professor of Innovation. UK national lead for Health and Innovation with China.

Matt Williams, JD
Board Chairman

SignalRX CEO. Experienced Executive and Managing Shareholder with 40 years experience in the practice of law. Skilled in negotiation, arbitration, mediation, complex transactions, legal writing, complex civil litigation, and appeals. Experienced entrepreneur.

Silvia Panigone, PhD, EMBA
Board Member, CEO

25 years in biotech, mid-size private & public, C-level roles & Board positions in Drug development, Investment Banking and VC. Track record of fund raising (over $100M raised), partnership deals and M&A, creating an exit for multiple biotechs. Former COO at NLS (NASDAQ:NLSP). Bracco, Quintiles, I-bankers securities, BSI Healthcapital, ADYA

Inhalis Therapeutics
Corso Elvezia, 4
CH-6900 Lugano
Switzerland

©2022 INHALIS

All rights reserved.

Policy  /  Credits